180 day exclusivity

all regulatory agencies seek to have an affordable health care for all patients (not to mention that generic alternatives are cheaper for the government). 
The exact purpose of the 180 days exclusivity is to encourage generic companies to develop those generic drugs, to submit their ANDA earlier under the Paragraph IV claim, i.e., challenging the validity of an innovator’s patent, and by that, to bring an affordable drug product to the market sooner. In order to minimize the risk for the generic companies, as for sure the innovator will take them to court on the claim of infringing the patent/s in question, the benefit of being the ONLY generic alternative to the expensive innovator’s drug is a huge incentive. After being exclusively on the market for 6 months, it would be very difficult for other generic companies to take your market share, as you have already established presence, confidence and knowledge with the health care organizations. Being that you are the only generic, you have only the innovator as a competition from the pricing standpoint, so you have 6 months in which you can market your drug at a very high profit margin. Once new generics will come into the picture, prices drop dramatically. 
You can read more about it here: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm079342.pdf


USFDA Is commited to get cheaper medicines to patients and increase competition among generic players. the 180 day exclusivity to generic company.companies who develops these generic drugs and submit their ANDA earlier under the Paragraph IV claim is to get players quicKly on the scene. is USFDA NOT SMART…………


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s